Indianapolis-based Eli Lilly reports Foundayo tied to modeled cuts in 10‑year diabetes and cardiovascular risk
In an Oct. 1, 2026 press release, Eli Lilly said post-hoc analyses of the ATTAIN-1 trial found oral GLP-1 Foundayo (orforglipron) was associated with reduced predicted 10‑year risk of type 2 diabetes and cardiovascular disease at 72 weeks versus placebo.
Eli Lilly announced on Oct. 1, 2026 that post-hoc modeling from the Phase 3 ATTAIN-1 trial showed Foundayo was associated with sizable reductions in predicted 10‑year cardiometabolic risk in adults with obesity or overweight and a weight‑related condition. At 72 weeks, estimated reductions in predicted type 2 diabetes risk versus placebo were about 45% (5.5 mg), 50% (9 mg) and 57% (17.2 mg); estimated cardiovascular disease risk reductions versus placebo were about 13%, 15% and 18% across those same doses. The company said the analyses were published in Diabetes, Obesity and Metabolism.
Lilly noted the findings, combined with research linking weight loss to cost savings, suggest Foundayo could help lower long‑term spending for patients and healthcare systems, but these results come from modeled, post‑hoc analyses rather than prospective outcomes on disease incidence or real‑world costs.
BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.